I had found the Lucanix study easily yesterday since it is the only vaccine-based study currently ongoing in San Diego. http://cancer.ucsd.edu/AboutUs/News/stories/Lucanix.asp.
Lucanix (belagenpumatucel-L) is a gene-based therapy in which tumor cells extracted from the host are modified in such a way that they inhibit secretion of a chemical growth factor that enables tumor cells to evade immune surveillance. The modified cells are then reintroduced to the host, where, by way of increased tumor antigen recognition, the immune system is rendered more effective in mounting a response.
It is a Phase III trial. Results of the two Phase II trials were promising: "Many subjects who received Lucanix™ at the same dose that will bee administered in this trial had long-term disease stability with a good quality of life. ...No significant adverse events were observed." http://clinicaltrials.gov/ct2/show/NCT00676507?term=lung+cancer+AND+san+die go+AND+vaccine&rank=2
Efficacy is to be evaluated in the third year (and ongoing for a total of 7 years), however an interim analysis will be performed at some midpoint. In either case, the vaccine has proven promising enough at extending survival (a 400% improvement in some subjects, which is remarkable) that the FDA granted fast-track status to this Phase III trial. If PhIII data prove as positive as PhII, the vaccine approval process will undoubtedly be fast tracked as well.
There is another Phase II/III vaccine trial (Recombinant Human EGF-rP64K/Montanide ISA 51), which has also showed promise in preliminary studies. It is recruiting but based in Malaysia.
There are additionally abundant studies going on locally at UCD and Sacramento, however most are chemotherapy-based trials. The sole vaccine-based study (GVAX, yet another immune response-enhancing autologous vaccine currently in Phase II, http://www.cancer.gov/clinicaltrials/SWOG-S0310) is for bronchoalveolar lung cancer; I gather yours is NSCLC. This study is no longer recruiting.
Basically, this entire field of endeavor looks to be very promising and is moving ahead with all due speed. Lucanix or some other autologous tumor vaccine will no doubt be appearing on the market in the not-distant future.




Add to the discussion